SELLAS Life Sciences Group Inc (SLS)
1.29
+0.02
(+1.57%)
USD |
NASDAQ |
May 02, 13:22
SELLAS Life Sciences Group Enterprise Value: 68.93M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 68.93M |
| April 30, 2024 | 67.24M |
| April 29, 2024 | 65.55M |
| April 26, 2024 | 79.62M |
| April 25, 2024 | 83.00M |
| April 24, 2024 | 84.12M |
| April 23, 2024 | 89.19M |
| April 22, 2024 | 84.12M |
| April 19, 2024 | 84.12M |
| April 18, 2024 | 83.00M |
| April 17, 2024 | 76.81M |
| April 16, 2024 | 73.99M |
| April 15, 2024 | 72.31M |
| April 12, 2024 | 72.87M |
| April 11, 2024 | 76.24M |
| April 10, 2024 | 75.68M |
| April 09, 2024 | 76.24M |
| April 08, 2024 | 78.78M |
| April 05, 2024 | 72.87M |
| April 04, 2024 | 70.06M |
| April 03, 2024 | 71.18M |
| April 02, 2024 | 63.87M |
| April 01, 2024 | 57.68M |
| March 28, 2024 | 54.30M |
| March 27, 2024 | 55.43M |
| Date | Value |
|---|---|
| March 26, 2024 | 57.11M |
| March 25, 2024 | 55.99M |
| March 22, 2024 | 56.48M |
| March 21, 2024 | 53.17M |
| March 20, 2024 | 54.82M |
| March 19, 2024 | 55.37M |
| March 18, 2024 | 43.82M |
| March 15, 2024 | 46.03M |
| March 14, 2024 | 64.88M |
| March 13, 2024 | 62.27M |
| March 12, 2024 | 57.48M |
| March 11, 2024 | 56.40M |
| March 08, 2024 | 52.26M |
| March 07, 2024 | 54.44M |
| March 06, 2024 | 49.65M |
| March 05, 2024 | 43.13M |
| March 04, 2024 | 42.26M |
| March 01, 2024 | 40.96M |
| February 29, 2024 | 41.39M |
| February 28, 2024 | 41.39M |
| February 27, 2024 | 41.39M |
| February 26, 2024 | 41.83M |
| February 23, 2024 | 38.18M |
| February 22, 2024 | 35.96M |
| February 21, 2024 | 34.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-1.486M
Minimum
Jun 30 2019
183.79M
Maximum
Jun 28 2021
44.77M
Average
29.00M
Median
Aug 18 2023
Enterprise Value Benchmarks
| Geron Corp | 1.973B |
| Immuneering Corp | -40.30M |
| Protagonist Therapeutics Inc | 1.147B |
| Akebia Therapeutics Inc | 252.49M |
| Moderna Inc | 34.07B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.136M |
| Total Expenses (Quarterly) | 8.177M |
| EPS Diluted (Quarterly) | -0.25 |
| Earnings Yield | -105.4% |
| Normalized Earnings Yield | -166.21 |